Recurring concern
Failure to identify clinically significant medication risks
Pin
Get email alerts
Request correctionFirst reported 30 Jul 2013•Latest report 3 Jun 2026
What this concern includes
Includes failures in medication review, reconciliation, prescribing or screening that concern recognising the clinical significance of a medicine, contraindication, interaction, toxicity, side-effect or existing medication.
Not included
- Excludes failures to administer, monitor or supply medication where the concern is not specifically the identification of medication-related risk.
- Excludes illicit or general drug-use hazards not tied to a medication-safety control.
- Excludes generic failures to recognise symptoms or deterioration unless the report explicitly links them to medication-related risk.
- Excludes generic communication, documentation or staffing deficiencies that are not dedicated to identifying medication risks.
- Reports
- 54
- Individual concerns
- 58
- Date range
- 2013–2026
- Stated actions
- 100
Distinct published reports
A report can raise multiple concerns
First to latest report issue date
Described in published responses
Reports over time
Reports over time
Reports about this concern issued each year.
* 2026 is projected from reports observed to 7 Sep 2026.
Most frequent recipients
Most frequent recipients
Reports about this concern sent to each recipient.
Concerns and responses across reports
Only concerns grouped under this recurring concern are included. Select any concern, action or position to view the source wording.
-
Concerns raised1
Lack of standardised guidance for asking questions about possible medication side effects
This report raised 2 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.3
-
Action
Use the Clozapine Clinic standard operating procedure and GASS to monitor and record clozapine side effects in electronic patient records.
Stated by Herefordshire and Worcestershire Health and Care NHS Trust -
Action
Re-issue the Clozapine Treatment Guidelines and clinic guidance to the mental health clinical workforce.
Stated by Herefordshire and Worcestershire Health and Care NHS Trust -
Action
Undertake follow-up to ensure newly appointed and existing staff are aware of and comply with both clozapine guidance documents.
Stated by Herefordshire and Worcestershire Health and Care NHS Trust
-
Concerns raised1
Limited awareness of the significance of salbutamol overuse in patients and families
This report raised 5 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
No linked response statementsNo respondent-stated action or position is linked to these concerns in the published data.
-
Concerns raised1
Failure to provide specific advice to stop Candesartan and identify its pregnancy risk
This report raised 5 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.5
-
Action
Implement and apply an SOP covering pregnancy-related safety checks for new medicines, including stopping or replacing medicines unsafe in pregnancy.
Stated by Riverview Surgery -
Action
Use reception tasks to trigger pregnancy coding, midwife referral checks and medication reviews, with duty-GP cover when unavailable.
Stated by Riverview Surgery -
Action
Warn women taking Candesartan or other ARB medicines about pregnancy risks and the need to stop immediately if pregnancy occurs.
Stated by Riverview Surgery
-
Action
Maintain a mandatory prescribing assessment within GP specialty training that assesses prescribing for pregnancy and other special groups.
Stated by Royal College of General Practitioners -
Action
Provide pregnancy-prescribing information resources and links through the RCGP Women’s Health toolkit.
Stated by Royal College of General Practitioners
-
Concerns raised1
Failure to scrutinise medication and medication changes
This report raised 10 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
No linked response statementsNo respondent-stated action or position is linked to these concerns in the published data.
-
Concerns raised1
Lack of awareness of opioid toxicity and accumulation risks in patients with kidney impairment or failure
This report raised 1 other concern. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.1
-
Action
Update and distribute local adult opioid-toxicity management guidelines, including interim advice based on national best-practice guidance.
Stated by Royal Free London NHS Foundation Trust
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.1
-
Position
Expert review concluded that the patient was unlikely to have experienced opioid toxicity, contrary to the concern raised.
Stated by Royal Free London NHS Foundation Trust
-
Concerns raised1
Lack of clinical staff awareness of Clozapine's potential fatal side effects
This report raised 1 other concern. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.3
-
Action
Raised clinician awareness of clozapine side effects by communicating associated risks to mental health chief pharmacists and health communities.
Stated by NHS England -
Action
Review clozapine product information and consider whether warnings for healthcare professionals, patients and carers can be clarified.
Stated by Medicines and Healthcare products Regulatory Agency -
Action
Engage relevant stakeholders during the clozapine product-information review to ensure regulatory documents meet patients’ and prescribers’ needs.
Stated by Medicines and Healthcare products Regulatory Agency
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.1
-
Position
Commenting on clinical decisions in specific cases, including those concerning clozapine, is outside the respondent’s remit.
Stated by Medicines and Healthcare products Regulatory Agency
-
Concerns raised1
Failure to assess the suitability of Olanzapine depot injections for in-patients who refuse vital signs checks
This report raised 3 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
No linked response statementsNo respondent-stated action or position is linked to these concerns in the published data.
-
Concerns raised1
Under-appreciation of the risks posed by elevated propranolol medication levels
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.1
-
Action
Complete a surveillance review of current evidence and discuss the findings with GP advisors regarding propranolol guidance.
Stated by National Institute for Health and Care Excellence
Respondent positions A position is what a respondent says about the concern when they do not describe a specific action.1
-
Position
The guideline will not be updated at this time because MHRA found no need for a safety communication and noted widespread safe propranolol use.
Stated by National Institute for Health and Care Excellence
-
Concerns raised1
Failure to consider the risks of prescribing opioids to patients with former opioid addiction
This report raised 1 other concern. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.4
-
Action
Deliver opioid-prescribing masterclass training to Stockport GPs and clinicians.
Stated by NHS Greater Manchester Integrated Care Board -
Action
Create, disseminate and use a seven-minute briefing based on learning from the Regulation 28 report.
Stated by NHS Greater Manchester Integrated Care Board -
Action
Publish and maintain continuing professional development updates on opioid use disorder, medicine dependence, withdrawal symptoms and opioid reduction.
Stated by Royal College of General Practitioners
-
Action
Develop, launch and widely circulate a repeat-prescribing toolkit supporting safer, collaborative prescribing processes and addressing opioid-prescribing safety concerns.
Stated by Royal College of General Practitioners
-
Concerns raised1
Failure to recognise when patients are receiving Aspirin only
This report raised 2 other concerns. They are not shown here because they do not form part of this recurring concern.
Responses linked to these concernsEach statement is shown once, even when linked to more than one concern.
Actions described in response An action is something a respondent says it has done, is doing, or plans to do in response to the concern raised.1
-
Action
Implement revised PCI pack wording clarifying provision of Dual Anti-Platelet Therapy.
Stated by Royal Cornwall Hospitals NHS Trust
Data last updated 7 September 2026